Tony Liu, AOBO's Chief Executive Officer and Chairman stated, "We are excited to add Anindya to our core management team at this crucial time of rapid business expansion. Anindya brings a deep understanding our Company, our sector and our corporate culture in addition to his invaluable capital markets experience, and long-standing credibility among global institutional investors."
Anindya Chatterjee stated, "As an equity analyst, I have interacted regularly with AOBO's investors and management team, and I am very pleased to accept this strategic role at a Company with such strong fundamental performance, exciting growth prospects, and cohesive team. With my investment research experience and knowledge of the capital markets, I look forward to enhancing and executing AOBO's key growth initiatives, including the acquisition strategy and navigating the U.S. capital markets."
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com.
Statements made in this press release are forward-looking and are made
pursuant to the safe harbor provisions of the Securities Litigation Reform
Act of 1995. Such statements involve risks and uncertainties that may cause
actual results to differ materially from those set forth in these
statements. The economic, competitive, governmental, technological and
other factors identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-K for the year ended December
31, 2007, may cause actual results or events to differ materially from
those described in the forward looking statements i
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2008 PR Newswire.
All rights reserved